- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00959127
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-438162 (MEK162).
This study has 3 parts. In the first part, patients with advanced solid tumors will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1. (Active, not recruiting)
In the second part of the study, patients with advanced or metastatic biliary cancer will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 25 patients from the US will be enrolled in Part 2. (Active, not recruiting)
In the third part of the study, patients with metastatic colorectal cancer (CRC) will receive the best dose of the study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 25 patients with KRAS mutation (Active, not recruiting) and 15 patients with BRAF mutation (Active, not recruiting) from the US will be enrolled in Part 3.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-1000
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Dana-Farber/Harvard Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- South Texas Accelerated Research Therapeutics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria (for Part 3):
- A histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma which is metastatic (measurable disease).
- Documented KRAS- or BRAF- tumor mutation.
- Previously treated with or unsuitable for treatment with 5-Fluorouracil (5-FU), oxaliplatin, irinotecan and, if available, bevacizumab.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Additional criteria exist.
Key Exclusion Criteria (for Part 3):
- Uncontrolled or symptomatic brain metastases (if the patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days).
- History of central serous retinopathy, retinopathy visible at baseline that would be considered a risk factor for central serous retinopathy or retinal vein occlusion.
- Concomitant malignancies or previous malignancies with less than a 2-year disease free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stage A low grade prostate cancer may enroll irrespective of the time of diagnosis.
- Prior treatment with a MEK inhibitor.
- Treatment with prior chemotherapy, anticancer immunotherapy, monoclonal antibodies or other protein or peptide therapeutics within 21 days of the first dose of study drug.
- Treatment with a small molecule targeted agent or anticancer hormonal therapy within 14 days of the first dose of study drug.
- Treatment with prior radiotherapy within 28 days of initiating study drug (if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy).
- Major surgery within 4 weeks or minor surgery within 7 days prior to the first dose of study drug.
- Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B.
- Additional criteria exist.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARRY-438162 (MEK 162)
|
Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Establish the maximum tolerated dose (MTD) of the study drug.
Time Frame: Part 1, one year
|
Part 1, one year
|
Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.
Time Frame: Parts 1, 2 and 3: two years
|
Parts 1, 2 and 3: two years
|
Characterize the pharmacokinetics (PK) of the study drug and metabolite.
Time Frame: Parts 1, 2 and 3: two years
|
Parts 1, 2 and 3: two years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the efficacy of the study drug in terms of tumor response, duration of response, duration of stable disease, progression-free survival and overall survival.
Time Frame: Parts 1, 2 and 3: two years
|
Parts 1, 2 and 3: two years
|
Assess possible PK/pharmacodynamic (PD) or PK/efficacy and safety correlations.
Time Frame: Parts 1, 2 and 3: two years
|
Parts 1, 2 and 3: two years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ARRAY-162-111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
Clinical Trials on ARRY-438162 (MEK162), MEK inhibitor; oral
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Melanoma | Stage IV MelanomaUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedRheumatoid ArthritisBrazil, Argentina, United States, Poland, Hungary, Peru, Romania
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Memorial Sloan Kettering Cancer CenterArray BioPharmaCompletedAdvanced BRAF Mutant CancersUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent Pancreatic Carcinoma | Locally Advanced Pancreatic CarcinomaUnited States
-
University of California, San FranciscoTakeda; Array BioPharmaTerminatedProgressive Disease | Stage IV Lung Cancer | Lung Non-Small Cell Carcinoma | ROS1 Gene Rearrangement | ALK Gene Rearrangement | Stage IIIB Lung Cancer | Stage IIIC Lung Cancer | Stage IVA Lung Cancer | Stage IVB Lung CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8United States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Array BioPharmaCompletedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States